Grifols, S.A. is engaged in the acquisition, manufacture, preparation and sale of therapeutic products, mainly plasma derivatives. The company operates through the bioscientific, hospital, diagnostic, biosupplies and other divisions.
トレード終了: ストップロスに到達:
28 Jul